Liu Dong-ying, Xie Guang-ru, Chen Ming
Department of Integrated Medicine, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2013 Feb;34(2):187-90.
Male breast cancer (MBC) is a rare disease, with clinical and prognostic features still controversial. The aim of this study was to discuss the clinical characteristics and prognosis of MBC.
Clinical data related to 71 MBC patients was reviewed.
The radio of MBC to female breast cancer (FBC) was 42:10 000. Age related to the diagnosis of MBC ranged from 43 to 84 years with the median age as 62 years old, older than the FBC patients (t = 6.355, P = 0.000). The percentage of invasive ductal carcinoma in MBC patients was much higher than in FBC patients (χ(2) = 29.875, P = 0.000). The positive rate of estrogen receptor (ER) was significantly higher than those in FBC patients and the positive rates of human epidermal growth factor receptor-2 (HER-2) were less frequently (χ(2) = 3.741, P = 0.048 and χ(2) = 12.845, P = 0.002) seen. Data from the univariate and multivariate analysis showed that the 3-, 5- and 10-year survival rates of MBC were 82.6%, 74.0% and 47.4% respectively, significantly higher than those in FBC patients (P = 0.004, P = 0.046). Patients with positive HER-2 showed worse prognosis than HER-2 negative patients in MBC patients (χ(2) = 4.219, P = 0.040).
There were significant clinic-pathologic and prognostic differences between FBC and MBC patients. The HER-2 positivity seemed to be an important factor for the prognosis and treatment of patients with MBC.
男性乳腺癌(MBC)是一种罕见疾病,其临床和预后特征仍存在争议。本研究旨在探讨MBC的临床特征及预后。
回顾了71例MBC患者的临床资料。
MBC与女性乳腺癌(FBC)的比例为42:10000。MBC诊断相关年龄范围为43至84岁,中位年龄为62岁,高于FBC患者(t = 6.355,P = 0.000)。MBC患者中浸润性导管癌的比例远高于FBC患者(χ(2)=29.875,P = 0.000)。雌激素受体(ER)阳性率显著高于FBC患者,而人表皮生长因子受体2(HER-2)阳性率则较低(χ(2)=3.741,P = 0.048;χ(2)=12.845,P = 0.002)。单因素和多因素分析数据显示,MBC的3年、5年和10年生存率分别为82.6%、74.0%和47.4%,显著高于FBC患者(P = 0.004,P = 0.046)。在MBC患者中,HER-2阳性患者的预后比HER-2阴性患者差(χ(2)=4.219,P = 0.040)。
FBC和MBC患者之间存在显著的临床病理和预后差异。HER-2阳性似乎是MBC患者预后和治疗的重要因素。